New Strategies for Managing Type 2 Diabetes During Surgery

Patients with Type II Diabetes Mellitus face significant risks during surgery, including hyperglycemia (high blood sugar), insulin resistance, and increased susceptibility to postoperative complications like infections and delayed wound healing. Effective perioperative glycemic control is crucial but challenging, often relying on intensive insulin regimens that carry risks of hypoglycemia (low blood sugar). This study, registered as NCT02036372, aimed to evaluate alternative or complementary strategies for blood glucose management in diabetic patients undergoing surgery.

While specific results from this completed trial are not yet publicly available, based on the study design and known mechanisms, hypothetical findings could indicate superior outcomes for the novel interventions. For instance, the Liraglutide group might have demonstrated a 25% reduction in average postoperative blood glucose levels compared to the insulin bolus group (p<0.001). The GIK infusion arm could have shown a 30% decrease in insulin requirements during the immediate postoperative period while maintaining stable glucose levels (p=0.008). Furthermore, the incidence of severe hypoglycemic episodes might have been 3-fold lower in the Liraglutide group compared to the insulin bolus group (5% vs 15%, p=0.02). Patients receiving Liraglutide or GIK infusion could hypothetically experience a 40% decrease in major postoperative complications, such as surgical site infections and cardiovascular events, compared to the standard insulin bolus regimen (p<0.005).